


Researchers identify a new protein that may contribute to Alzheimer's disease

17 October 2022



Overview of study. Brain tissue from the prefrontal cortex was acquired for 43 individuals, and TBS-soluble extracts prepared. Tissue was extensively dialyzed in BrainPhys media to remove small molecules, such as glutamate, present in the extracts. Extracts were analyzed by proteomic profiling, and 1841 proteins quantified. These extracts were used either in a neurite integrity assay and/or in an MEA-based spontaneous activity assay. Correlations were then calculated between proteins quantified via proteomics and activity in each assay. Credit: *Molecular Neurodegeneration* (2022). DOI: 10.1186/s13024-022-00558-4

Alzheimer's disease (AD) currently has no cure and is predicted to affect over 100 million people worldwide by 2050. Ongoing research is focused on two key neurotoxic proteins: amyloid beta (A β) and tau. While these proteins have been shown to be associated with AD, for some people with the disease, the levels of A β and tau do not consistently explain or correlate with the severity of cognitive decline.

To identify other proteins that may be directly involved with fundamental aspects of AD, like synaptic loss and neurodegeneration, investigators at Brigham and Women's Hospital, a founding member of the Mass General Brigham health care system, exposed laboratory neurons to [human brain](#) extracts from about 40 people who either had AD, were protected from AD despite having high

A β and tau levels, or were protected from AD with little or no A β and tau in their brains.

The researchers identified and validated ganglioside GM2 activator (GM2A) as a protein able to reduce neuronal firing and induce a loss of neurite integrity. These protein characteristics may contribute to the cause of AD, progression of the disease, or both.

"Our data helps identify a new and potentially important protein that may be associated with the pathogenesis of Alzheimer's disease," said senior author Tracy Young-Pearse, Ph.D., from the Department of Neurology. "Interestingly, GM2A has been previously implicated as a causative agent in a [lysosomal storage disorder](#) very similar to Tay-Sachs disease, another condition like AD that destroys neurons."

The research was published in *Molecular Neurodegeneration*.

More information: Yi-Chen Hsieh et al, Elevated ganglioside GM2 activator (GM2A) in human brain tissue reduces neurite integrity and spontaneous neuronal activity, *Molecular Neurodegeneration* (2022). DOI: [10.1186/s13024-022-00558-4](https://doi.org/10.1186/s13024-022-00558-4)

Provided by Brigham and Women's Hospital

APA citation: Researchers identify a new protein that may contribute to Alzheimer's disease (2022, October 17) retrieved 21 October 2022 from <https://medicalxpress.com/news/2022-10-protein-contribute-alzheimer-disease.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.